# A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

> **NCT03574584** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 37 (actual)

## Conditions studied

- Metabolism and Nutrition Disorders
- Overweight or Obesity

## Interventions

- **DRUG:** NNC0165-1562
- **DRUG:** Semaglutide
- **DRUG:** Placebo (NNC0165-1562)

## Key facts

- **NCT ID:** NCT03574584
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2019-07-27
- **Final completion:** 2019-07-27
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574584, "A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03574584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*